Literature DB >> 3232554

Virilization due to ovarian hyperthecosis in a postmenopausal woman.

C van Heyningen1, I A MacFarlane, M J Diver, C Muronda, D Tuffnell.   

Abstract

A 51-year-old woman presented with hirsutism and virilization of gradual onset. The serum gonadotropin concentrations were in the postmenopausal range, the serum testosterone concentration was markedly elevated (9.8 nmol/l) and the serum estradiol concentration (220 pmol/l) was elevated above the postmenopausal range. A selective venous catheterization study demonstrated raised serum testosterone and androstenedione levels in ovarian veins and suggested the presence of a left ovarian tumor. The raised peripheral estradiol level was shown to be due to ovarian hypersecretion. After bilateral oophorectomy the serum testosterone became normal. Ovarian histology revealed bilateral stromal hyperthecosis. Ovarian hyperthecosis is a rare but important cause of serum testosterone levels in the neoplastic range. This is the third case reported of postmenopausal virilization due to ovarian hyperthecosis and the first report of a selective venous catheterization study in such a patient.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3232554     DOI: 10.3109/09513598809107656

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  3 in total

Review 1.  Virilization in a postmenopausal woman due to ovarian stromal hyperthecosis.

Authors:  J M Goldman; L J Kapadia
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

2.  Two patients with marginal symptoms showing hyperthecosis at the edge of malignancy: Presentation of two cases.

Authors:  Sinan Beksac; Ilker Selçuk; Gökhan Boyraz; Güneş Güner; Mert Turgal; Alp Usubutun
Journal:  J Turk Ger Gynecol Assoc       Date:  2013-07-10

Review 3.  Selective venous sampling for androgen-producing ovarian pathology.

Authors:  Eric D Levens; Brian W Whitcomb; John M Csokmay; Lynnette K Nieman
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-21       Impact factor: 3.478

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.